-
Mashup Score: 1Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens - 1 year(s) ago
Renal cell carcinoma (RCC) comprises a group of malignancies arising from the kidney with unique tumour-specific antigen (TSA) signatures that can trigger cytotoxic immunity. Two classes of TSAs are now considered potential drivers of immunogenicity in RCC: small-scale insertions and deletions (INDELs) that result in coding frameshift mutations, and activation of human endogenous retroviruses….
Source: www.nature.comCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 0COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS - 1 year(s) ago
The contemporaneous presence of immune defects and heart diseases in patients with 22q11.2 deletion syndrome (22q11.3DS) might represent risk factors for severe coronavirus 2019 disease (COVID-19).
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #COVID-19 Severity, #Cardiological Outcome, and #Immunogenicity of #mRNA #Vaccine on #Adult #Patients With 22q11.2 DS #JACIPCOVID https://t.co/V7u4s2qWly https://t.co/UVBAqDiloV
-
-
Mashup Score: 0Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody Deficiency - 1 year(s) ago
Common variable immunodeficiency (CVID) is characterized by an impaired post-vaccination response, high susceptibility to respiratory tract infections, and a broad spectrum of non-infectious complications. Thus, patients with CVID may be at high risk of coronavirus disease (COVID-19), and vaccination’s role in prevention is questionable.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! #Clinical #outcomes, #immunogenicity, and #safety of #BNT162b22 #Vaccine in #Primary #Antibody #Deficiency https://t.co/GDOMHLHG7E
-
-
Mashup Score: 0
Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in patients with SLE and rheumatoid arthritis (RA). Methods Patients with SLE and RA aged 18–65 years who completed a series of inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines for at least 28 days were enrolled. Immunogenicity assessment was done before and day 15 after each…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
#Epidemiology This week on LSM: Third #BNT162b2 #booster significantly improved #humoral & #cellular #immunogenicity in patients with #SLE & #RA. The #benefit of a short-interval fourth booster in #patients with #suboptimal #humoral #response was unclear https://t.co/A67fzCDgEg
-
-
Mashup Score: 0
Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in patients with SLE and rheumatoid arthritis (RA). Methods Patients with SLE and RA aged 18–65 years who completed a series of inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines for at least 28 days were enrolled. Immunogenicity assessment was done before and day 15 after each…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
#Epidemiology This week on LSM: Third #BNT162b2 #booster significantly improved #humoral & #cellular #immunogenicity in patients with #SLE & #RA. The #benefit of a short-interval fourth booster in #patients with #suboptimal #humoral #response was unclear https://t.co/A67fzCDgEg
-
-
Mashup Score: 0
Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in patients with SLE and rheumatoid arthritis (RA). Methods Patients with SLE and RA aged 18–65 years who completed a series of inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines for at least 28 days were enrolled. Immunogenicity assessment was done before and day 15 after each…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
#Epidemiology This week on LSM: Third #BNT162b2 #booster significantly improved #humoral & #cellular #immunogenicity in patients with #SLE & #RA. The #benefit of a short-interval fourth booster in #patients with #suboptimal #humoral #response was unclear https://t.co/A67fzCDgEg
-
-
Mashup Score: 0
This work was supported, in whole or in part, by funding from CEPI and the Bill & Melinda Gates Foundation Investment ID OPP1148601. The Bill & Melinda Gates Foundation supported this project for the generation of IND-enabling data and CEPI supported this clinical study.
Source: PubMedCategories: Critical Care, Latest HeadlinesTweet-
Safety and #immunogenicity of a #SARS- #CoV-2 #recombinant #protein #nanoparticle #vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial https://t.co/bdRULKwjli https://t.co/PZWNAYTm6j
-
-
Mashup Score: 2
Objective To assess the antibody response to disease-modifying antirheumatic drug (DMARD) therapy after the first and second dose of the ChAdOx1nCov-19 (AstraZeneca (AZ)) and BNT162b (Pfizer) vaccines in patients with immune-mediated inflammatory disease (IMID) compared with controls and if withholding therapy following the first vaccination dose has any effect on seroconversion and SARS-CoV-2…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet-
Multicentre three-arm randomised controlled trial compared the #immunogenicity of the #Pfizer and #AZ #COVID vaccines in 181 IMID patients on DMARDs 2 shots and 2 strategies (continue treatment or paused) vs controls Read more: https://t.co/1eyE9nyWS5 https://t.co/DV5nSEgtcT
-
-
Mashup Score: 0Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours - 2 year(s) ago
Patients with cancer are at an increased risk of severe COVID-19. Breakthrough infections after two vaccinations do occur and can be lethal.1–3 Most patients treated for a solid tumour develop an adequate humoral response against SARS-CoV-2 after two vaccinations; however, antibody concentrations tend to be lower when vaccinations are administered during chemotherapy, resulting in a suboptimal…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Comment: #Immunogenicity after second and third mRNA-1273 #vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours https://t.co/dGNfnnr7oH #COVIDvaccine #cancer
-
-
Mashup Score: 1NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens - 2 year(s) ago
This article is featured in Top Reads , p.[][1] [1]: /lookup/volpage/208/1515
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet-
#JI_TopRead from @KTHastingsMDPhD @ImmunologyUA | mathematical model better predicts responsiveness to #immunotherapy based on Ag #immunogenicity #ReadTheJI #immunology #tumorimmunity @ES_Borden @UAZHealth https://t.co/xsWPhAH6tp https://t.co/dKsQOsjLTT
-
New Review online! #Immunogenicity in #RCC: shifting focus to alternative sources of tumour-specific antigens @MelissaMWolf1 @KimrynRathmell @AguirreDC2 https://t.co/vRR6LAnfAW https://t.co/H70dlbmuT8